May 25, 2016 (View All Issues)
- Lenvatinib (Lenvima), in combination with everolimus (Afinitor), for the treatment of...
- Join the discussion: Use #ASCO16 on Twitter to follow and participate in the conversation around the Annual Meeting in real time! During last year’s Annual Meeting, more than 12,400 individuals sent over 59,000 tweets, reaching an estimated 262 million people on Twitter. Tweets about the...
Site of Tumor Impacts Survival and Choice of Treatment in Metastatic Colorectal Cancer
In metastatic colorectal cancer, the anatomic location of the tumor within the colon appears to make a difference in overall survival as well as response to pivotal treatments, according to a retrospective analysis of the pivotal CALGB/SWOG 80405 (Alliance) trial.1 “While previous studies had...
In Celebration of a Remarkable Career at ASCO
In March, ASCO announced that Allen S. Lichter, MD, FASCO, was stepping down as Chief Executive Officer (CEO) at the end of June, ending his 10-year tenure as head of the Society and the Conquer Cancer Foundation of ASCO. Clifford A. Hudis, MD, FACP, Chief of Breast Medicine Service and Vice...
What ASCO Can Do for You—and for Our Patients
This is an exciting time to be an oncologist. I often say I wish I were 30 again and just starting out in my oncology career. Never before have we had such sophisticated technology for evaluation of the tumor or such a potent arsenal of targeted and effective therapies to treat cancer. Further, the ...
Pembrolizumab Survival Benefit Proves Durable in Patients With Advanced Melanoma
With new immunotherapies available for the treatment of advanced melanoma, an important question is how best to combine and sequence them. Long-term follow-up from the KEYNOTE-001 trial suggests that pembrolizumab (Keytruda) can improve survival in newly diagnosed patients and in those treated...
Upfront Transplant Remains Standard of Care in Multiple Myeloma
Upfront autologous stem cell transplant remains the standard of care in patients with newly diagnosed multiple myeloma, even in the era of novel agents, according to a phase III study of the European Myeloma Network.1 “Our findings show that autologous stem cell transplant should remain the...
Maximizing Cancer Cure: How Do We Get There?
Is cancer really “curable,” and if so, how? For a “Cancer Dialogue” held during the 2016 American Association of Cancer Research (AACR) Annual Meeting, half a dozen stellar participants from the research, industry, regulatory, and advocacy communities convened to debate the topic. The ASCO Post was ...
Meta-analysis of Breast Cancer Studies Demonstrates Value of Pathologic Complete Response
In a meta-analysis of neoadjuvant studies totaling over 18,000 patients, achievement of pathologic complete response was associated with significantly reduced disease recurrence and mortality across the various breast cancer subtypes. Laura Spring, MD, a senior medical oncology fellow at...
Durable Benefit With Immunotherapy Combination in Advanced Melanoma
With the recent explosion in immunotherapies for advanced melanoma and other tumors, all eyes are on how best to sequence or combine these therapies. Initial reports of overall survival from the phase II randomized CheckMate 069 trial suggest that the combination of ipilimumab (Yervoy, an...
AACR Congratulates Newest National Academy of Sciences Members
The American Association for Cancer Research (AACR) congratulates its 10 members who have been elected to the National Academy of Sciences (NAS), in recognition of distinguished and continuing achievements in original research. The Academy elected a total of 84 new members and 21 foreign associates ...
William G. Kaelin, Jr, MD, Receives AACR Princess Takamatsu Award
William G. Kaelin, Jr, MD, Chair of the Executive Committee for Research at Dana-Farber Cancer Institute, received the 10th annual Princess Takamatsu Award for “novel and significant work” in cancer from the American Association for Cancer Research (AACR).
Dr. Kaelin, who is Professor of...
FDA Approves Nivolumab for Heavily Pretreated Classical Hodgkin Lymphoma
On May 17, 2016, the U.S. Food and Drug Administration (FDA) granted accelerated approval to the programmed cell death protein 1 (PD‑1) inhibitor, nivolumab (Opdivo), for the treatment of patients with classical Hodgkin lymphoma that has relapsed or progressed after autologous hematopoietic stem...
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): 2016 Guidelines
In 1996, the National Comprehensive Cancer Network (NCCN®) published its first set of Clinical Practice Guidelines in Oncology® (NCCN Guidelines®), covering eight tumor types. The NCCN Guidelines® are now published for more than 60 tumor types and topics. Some of the key updates for 2016 were...
Cases of Mixed Hepatocellular Carcinoma–Cholangiocarcinoma Emerging
Combined hepatocellular carcinoma–cholangiocarcinoma is a histopathologically distinct tumor for which no formal treatment guidelines exist. It is also a malignancy that is being diagnosed more often, according to researchers from Mount Sinai Beth Israel Medical Center, New York, who reported...
Highlights From the 2016 AACR Annual Meeting
This year’s Annual Meeting of the American Association for Cancer Research (AACR) featured outstanding research in the field of cancer, as well as an inspiring talk by Vice President Joe Biden (see the May 10 issue of The ASCO Post). Here are some summaries of studies that warrant attention; they...
AACR Inducts 2016 Class of Fellows of the AACR Academy
The American Association for Cancer Research (AACR) has announced its 11 newly elected Fellows of the AACR Academy.
The AACR Academy serves to recognize and honor distinguished scientists whose major scientific contributions have propelled significant innovation and progress against cancer. All...
Crizotinib Active in Orphan Kidney Malignancy
Crizotinib (Xalkori) achieved overall and durable responses in advanced inoperable papillary renal cell carcinoma type 1 characterized by somatic MET mutations, according to an investigator-initiated trial conducted by the European Organization for Research and Treatment of Cancer (EORTC).1
...
Expert Point of View: Mayer Fishman, MD, PhD
“This was a difficult study to conduct. It required 13 centers in 8 countries over 3 years to recruit these patients—that’s about 1 patient per site per year,” said Mayer Fishman, MD, PhD, of Moffitt Cancer Center in Tampa, Florida. “It’s an important study, because these patients are typically ...
Gene Rearrangements: Attractive Targets in a Variety of Cancers
Entrectinib, a potent investigational tyrosine kinase inhibitor, exhibited promising clinical activity in a pooled analysis of two phase I trials of patients with solid metastatic tumors that harbored any of five specific genetic rearrangements involving NTRK1, NTRK2, NTRK3, ROS1, or ALK.
...
10 Things You Need to Know About the Cancer MoonShot 2020 Program
In the fall of 2015, Vice President Joe Biden called for a “moonshot” to cure cancer. In his final State of the Union Address on January 12, 2016, President Barack Obama reemphasized that goal, stating, “Let’s make America the country that cures cancer once and for all.” To achieve that goal, the ...
FDA Grants Selumetinib Orphan Drug Designation for Adjuvant Treatment of Differentiated Thyroid Cancer
Earlier this month, AstraZeneca announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation for the investigational MEK1/2 inhibitor selumetinib for adjuvant treatment of patients with stage III or IV differentiated thyroid cancer.
Selumetinib inhibits the MEK...
Venetoclax for Previously Treated Chronic Lymphocytic Leukemia With 17p Deletion
On April 11, 2016, venetoclax (Venclexta) was approved for treatment of patients with chronic lymphocytic leukemia (CLL) with 17p deletion, as detected by a U.S. Food and Drug Administration (FDA)-approved test, who have received at least one prior therapy.1,2 The accelerated approval was based...
FDA Maintains Ongoing Efforts to Expedite Drug Approvals
The U.S. Food and Drug Administration (FDA) is continuing its efforts to expedite oncology-hematology drug approvals. As of May 15, 2016, FDA has approved the following agents since January of this year.
ODAC Advises the FDA to Wait for Phase III Results for Rociletinib in Non–Small Cell Lung Cancer
The U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) met April 12 to consider a New Drug Application by Clovis Oncology for rociletinib, an investigational therapy for epidermal growth factor receptor (EGFR)-mutated non–small cell lung cancer (NSCLC) in patients...
Young Women Require Formal Assessment to Identify Breast Cancer Risk
Half of the young women presenting to an academic surgical breast practice would qualify for mammography screening starting at age 40. According to the newly updated guidelines, these young at-risk women may be missed, researchers reported at the 2016 American Society of Breast Surgeons (ASBS)...
Dr. Susan Love: Time to Address ‘Collateral Damage’ of Breast Cancer Treatment
The “collateral damage” of cancer treatment is a topic that is familiar to Susan Love, MD, MBA. As a breast cancer surgeon and chief visionary officer of Dr. Susan Love Research Foundation, she has learned much about the consequences of cancer treatment. But she came by an important aspect of her ...
Is Male Breast Cancer Overlooked in Clinical Trials?
Three and a half years ago, Oliver Bogler, PhD, a cancer biologist and Senior Vice President of Academic Affairs at the University of Texas MD Anderson Cancer Center, saw his personal and professional worlds collide. He received a cancer diagnosis—one that mirrored his wife’s.
“Some might say...
Andrew Bindman, MD, Named New AHRQ Director
Andrew Bindman, MD, a primary care physician with federal and state health policy experience who has practiced, taught, and conducted health services research at San Francisco General Hospital, has been named the new Director of the Agency for Healthcare Research and Quality (AHRQ). Dr. Bindman...
Lifang Hou, MD, PhD, Named Director of Global Health at the Lurie Cancer Center
Lifang Hou, MD, PhD, has been appointed Director of Global Health for the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. Dr. Hou brings her extensive experience in identifying risk factors and molecular biomarkers predictive of cancer risk and mortality, her interest in...
Neratinib Improves Invasive Disease–Free Survival in HER2-Positive Breast Cancer
In the phase III ExteNET trial reported in The Lancet Oncology, Arlene Chan, MD, of the Breast Cancer Research Centre-Western Australia, Perth, and colleagues found that 1 year of treatment with the HER1, HER2, and HER4 tyrosine kinase inhibitor neratinib improved invasive disease–free survival ...
ExteNET Trial of Neratinib: One Size Does Not Fit All in HER2-Positive Breast Cancer
Neratinib is an oral anti-HER2 tyrosine kinase inhibitor that has shown promising activity in the treatment of HER2-positive metastatic breast cancer.1 It differs from monoclonal antibodies such as trastuzumab (Herceptin) because, as a small molecule, neratinib blocks the ATP binding site on the...
No Survival Benefit Reported With Chemoradiotherapy vs Continued Chemotherapy in Controlled Locally Advanced Pancreatic Cancer
In the phase III GERCOR LAP07 trial reported by Pascal Hammel, MD, of Beaujon Hospital, Clichy, France, and colleagues in JAMA, there was no survival benefit of chemoradiotherapy vs continued chemotherapy in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine...
ASCO Urges Aggressive Efforts to Increase HPV Vaccination and Prevent Cancer
On Monday, April 11, ASCO released a policy statement calling on member oncologists to help lead a push for all adolescents and young adults to be vaccinated against cervical and other cancer.
Use of human papillomavirus (HPV) vaccines should be rapidly expanded to protect thousands of young...
Four Reasons to Use Social Media at the ASCO Annual Meeting
Enhance Your Annual Meeting Experience With Attendee Resources
Next month, more than 30,000 oncology professionals will gather in Chicago for the 2016 ASCO Annual Meeting. This year’s theme, “Collective Wisdom: The Future of Patient-Centered Care and Research,” highlights the value of the combined knowledge of the global oncology community, spanning across...
A Quick Look at the Benefits of HPV Vaccination
In the United States, only 36% of girls and 14% of boys ages 11 to 13 are fully vaccinated against HPV. Last month, ASCO addressed this issue in a statement urging aggressive efforts to increase vaccination and prevent cancer. Your patients can quickly learn some facts about this underused form of...
ASCO Endorses European Association of Urology Guideline on Muscle-Invasive and Metastatic Bladder Cancers
As reported in the Journal of Clinical Oncology by Matthew I. Milowsky, MD, of the University of North Carolina Lineberger Comprehensive Cancer Center, and colleagues,1 ASCO has endorsed the European Association of Urology clinical practice guideline on muscle-invasive and metastatic bladder...
ASCO and European Association of Urology Agree on Bladder Cancer Guidelines
I like economies of scale, and thus it makes perfect sense that ASCO has set a formal process to allow potential endorsement of selected guidelines from other organizations, rather than redoing the whole process. Recently, we have seen the publication of a formal endorsement of the European...
No Disease-Free Survival Benefit of Adjuvant Sunitinib or Sorafenib in High-Risk Nonmetastatic Renal Cell Carcinoma
In the phase III ECOG-ACRIN E2805 trial reported in The Lancet by Naomi B. Haas, MD, of Abramson Cancer Center, University of Pennsylvania, and colleagues, no benefit of adjuvant vascular endothelial growth factor receptor (VEGFR) inhibitor treatment with sunitinib or sorafenib (Nexavar) was...
Curb Your Enthusiasm: No Benefit of Adjuvant Sorafenib or Sunitinib in Nonmetastatic Renal Cell Carcinoma
Renal cell carcinoma is the most common cancer of the kidneys. Up to 30% of patients present with advanced/metastatic disease, and recurrence can develop in patients at high risk treated by nephrectomy for localized tumors. Renal cell carcinoma is notoriously resistant to chemotherapy and...
Al B. Benson III, MD, Elected President of the National Patient Advocate Foundation Executive Board
Al B. Benson III, MD, Associate Director for Cooperative Groups at the Lurie Cancer Center, has been elected President of the National Patient Advocate Foundation’s (NPAF) Executive Board. An oncologist and Professor of Medicine in the Division of Hematology/Oncology at the Feinberg School of...
Suresh Senan, MRCP, FRCR, PhD, Receives 2016 Heine H. Hansen Award
The European Society for Medical Oncology (ESMO) and the International Association for the Study of Lung Cancer (IASLC) have announced the 2016 Heine H. Hansen (HHH) Award recipient: Suresh Senan, MRCP, FRCR, PhD. The award was presented at the European Lung Cancer Conference (ELCC) 2016, held on ...
Anti–PD-L1 Antibody Atezolizumab Active in Previously Treated Advanced Urothelial Carcinoma
In a phase II trial reported in The Lancet, Jonathan E. Rosenberg, MD, of Memorial Sloan Kettering Cancer Center, and colleagues found that the anti–PD-L1 (programmed cell death ligand 1) antibody atezolizumab produced durable responses in a marked proportion of patients with previously treated ...
Atezolizumab in Previously Treated Advanced Urothelial Carcinoma
The recent study by Rosenberg et al in The Lancet—summarized in this issue of The ASCO Post—is a very important paper in the field of bladder cancer therapy.1 It is the first phase II trial in metastatic transitional cell carcinoma that demonstrates the single-agent activity of the...
FDA Approves Lenvatinib in Combination With Everolimus in Advanced Renal Cell Carcinoma
On May 13, 2016, the U.S. Food and Drug Administration (FDA) approved lenvatinib capsules (Lenvima) in combination with everolimus (Afinitor) for the treatment of advanced renal cell carcinoma following one prior antiangiogenic therapy. Lenvatinib was first approved in 2015 for the treatment of...
Increased Physical Activity Associated With Lower Risk of 13 Types of Cancer
A new study of the relationship between physical activity and cancer has shown that greater levels of leisure-time physical activity were associated with a lower risk of developing 13 different types of cancer. The risk of developing seven cancer types was 20%, or more, lower among the...
Eribulin Improves Overall Survival vs Dacarbazine in Previously Treated Advanced Liposarcoma or Leiomyosarcoma
In a phase III trial reported in The Lancet, Patrick Schöffski, MD, of University Hospitals Leuven, Leuven Cancer Institute, Belgium, and colleagues found that eribulin (Halaven) improved overall survival vs dacarbazine in patients with advanced or metastatic soft-tissue sarcoma who had...
Eribulin in Liposarcoma: A Closer Look at the Comparative Data
Sarcoma therapy is a challenge for oncologists. Soft-tissue sarcomas encompass more than 50 different histologies, resulting in limited familiarity of management for many treating physicians. In addition, there have been few available effective therapies. The phase III trial of eribulin...
NIH Appoints Patricia Flatley Brennan, RN, PhD, to Lead the NLM
National Institutes of Health (NIH) Director Francis S. Collins, MD, PhD, has named Patricia Flatley Brennan, RN, PhD, Director of the National Library of Medicine (NLM). The NLM is the world’s largest biomedical library and the producer of digital information services used by scientists,...
Brian Czerniecki, MD, PhD, Named Chair of Breast Oncology at Moffitt
Moffitt Cancer Center has announced that Brian Czerniecki, MD, PhD, has joined the faculty and will serve as the Chair and a member of the Department of Breast Oncology.
Dr. Czerniecki is recognized for his contribution to the development of sentinel lymph node mapping. He joins Moffitt after...
Robert S. Langer, ScD, Receives 2016 AACR-Irving Weinstein Foundation Distinguished Lectureship
The American Association for Cancer Research (AACR) honored Robert S. Langer, ScD, with the 2016 AACR-Irving Weinstein Foundation Distinguished Lectureship at the AACR Annual Meeting 2016, held in New Orleans, on April 16–20.
The AACR-Irving Weinstein Foundation Distinguished Lectureship was...
ASCO Past-President Anticipates a New Position With an Ongoing Goal of Advancing the Field of Oncology
After an extensive national search, Hartford HealthCare has appointed ASCO Past-President Peter Paul Yu, MD, FACP, FASCO, as the first Physician-in-Chief of the Hartford HealthCare Cancer Institute. As Physician-in-Chief, Dr. Yu will be responsible for working closely and collaboratively with...
$200 Million Gift Launches Lawrence J. Ellison Institute for Transformative Medicine of USC
Technology entrepreneur Larry Ellison has donated $200 million to establish the Lawrence J. Ellison Institute for Transformative Medicine of the University of Southern California (USC), a new center in Los Angeles that will combine interdisciplinary research with the holistic prevention and...
AUA, SUO Release New Clinical Practice Guideline on the Diagnosis and Treatment of Non–Muscle-Invasive Bladder Cancer
The American Urological Association (AUA), together with the Society for Urologic Oncology (SUO), has released a new clinical practice guideline on non–muscle-invasive bladder cancer. This new document outlines guidance on a variety of topics, including diagnosis and treatment, as well as a...
ASCO’s State Affiliate Council Improves Communication Between ASCO and Community Physicians
ASCO established a State Affiliate Council in 2012 consisting of representatives from each of the Society’s 48 state or regional oncology societies. The Council met on April 21–22 at ASCO headquarters in Alexandria, Virginia.
The ASCO Post talked with Paul Celano, MD, FACP, President,...
Leading Surgical Oncology Societies Call for Global Curriculum to Address Variations, Inadequacies in Training
The lack of an adequately trained workforce of surgical oncologists can be a major detriment in efforts to address the rising global cancer burden, according to two leading international surgical oncology societies.
In two jointly published reports,1,2 the Society of Surgical Oncology (SSO) and...
A Physician’s Guide to Pain and Symptom Management in Cancer Patients
Despite growing awareness and the existence of guidelines, undertreatment of cancer pain remains a persistent dilemma in the oncology community. Researchers from The University of Texas MD Anderson Cancer Center found that more than 33% of patients suffering from invasive cancer do not receive...
A Toolkit for Dealing With the Trauma of a Prostate Cancer Diagnosis
This year, an estimated 180,890 men in the United States will be diagnosed with prostate cancer; about 21,120 men die of the disease each year. On top of these sobering statistics, from screening to diagnosis and treatment, prostate cancer is fraught with controversy, creating untoward anxiety...
A Perilous Time for Refugees With Cancer
The numbers are difficult to fathom. According to a report by the United Nations High Commissioner for Refugees (UNHCR), in 2015, over 60 million people worldwide were forcibly displaced as a result of conflict, persecution, generalized violence, or human rights violations.1 Over 9 million of those ...
Occupational Therapy for Adults With Cancer: An Unmet Need
Adults with cancer are at high risk for functional limitations that would negatively affect their quality of life. Occupational therapy offers a range of supportive services, with the specific goal of helping these patients engage in life as independently as possible. To provide a better...
The Role of Occupational and Physical Therapy in Geriatric Oncology
With individuals aged 65 and older accounting for more than 50% of the U.S. population diagnosed with cancer,1 the demand for occupational and physical therapists to treat this population will increase in the years to come. Thus, it is essential for primary care providers to know that the...
Monitoring Survivors of Childhood Cancers for Late Effects of Treatment
This past January, ASCO held its inaugural Cancer Survivorship Symposium, which brought together the fields of medical oncology and primary care to address the critical need for coordinated care for cancer survivors. Among the presenters at the symposium was Smita Bhatia, MD, MPH, who gave the...
A Psychotherapist’s Approach to End-of-Life Care
Title: Dying: A Transition
Author: Monika Renz, PhD; translated by Mark Kyburz and John Peck
Publisher: Columbia University Press
Publication date: October 2015
Price: $38.00; hardcover, 176 pages
The night before Julius Caesar was assassinated, he had dinner with his friend...
Oncology and Diplomacy in the Middle East
The Middle East is a vast region comprised largely of developing nations with complicated sociopolitical challenges, violent internecine disputes, and deeply fragmented health-care systems. Not surprisingly, the region’s suboptimal health care contributes to the late diagnosis and poor survival ...
Mary Jackson Scroggins Receives 2016 AACR Distinguished Public Service Award
The American Association for Cancer Research (AACR) honored Mary “Dicey” Jackson Scroggins with the 2016 AACR Distinguished Public Service Award as part of the Opening Ceremony for the AACR Annual Meeting 2016, held in New Orleans on April 16–20, 2016. She was recognized for her long-standing...
The Arrival of Generic Imatinib Into the U.S. Market: An Educational Event
Imatinib mesylate (Gleevec), a Bcr-Abl tyrosine kinase inhibitor, is approved therapy for chronic myeloid leukemia (CML) in the United States. Imatinib is a miraculous drug that results in a normal functional lifespan in most patients with CML who can afford and comply with the treatment and...
How Immunotherapy Is Revolutionizing Cancer Care
More than 100 years after William B. Coley, MD, used bacterial toxins to goad the immune system into recognizing cancer cells as foreign to the body and mount an immune response to go after and kill them, the recognition of immunotherapy as a powerful anticancer therapy is finally...
Recent Reports on Treatment for Leukemias, Sinusoidal Obstruction Syndrome, and Graft-vs-Host Disease
In this installment of Hematology Expert Review, I will summarize five studies from the recent literature addressing important questions about leukemias and their treatment, anticoagulant therapy with the new agent defibrotide (Defitelio), and the use of antilymphocyte globulin to prevent chronic ...
Breast Cancer Research Foundation: Revitalizing Academic Research in Breast Cancer Through Drug Research Collaborative
When Evelyn H. Lauder was diagnosed with breast cancer in 1989, she became a vocal spokesperson for women’s health, and in 1993, along with Larry Norton, MD, now Deputy Physician-in-Chief for Breast Cancer Programs and Medical Director of the Evelyn H. Lauder Breast Center at Memorial Sloan...
2016 Oncology Meetings
MAY
Lymphoma: State-of-the-Art in Biology Therapy, and Patient Care
May 13-14 • New York, New York
For more information:
msklymphoma2016.com
NCI “Sandpit” on Individual and Contextual Factors of Population-Level Cancer Control
May 16-18 • Montgomery County, Maryland
For more information:
CancerLinQ Completes Agreements With 36 ‘Vanguard’ Practices
CancerLinQ LLC announced on April 21 that it has completed agreements with 36 oncology practices from around the country to begin implementing CancerLinQ™, the groundbreaking health information technology platform that will harness big data analytics to help oncologists rapidly improve high-quality ...
$3 Million NCI Grant Awarded to Study Links Between Liver Cancer and HIV
Vincent Lo Re, MD, MSCE, Assistant Professor of Medicine in the Division of Infectious Diseases and Epidemiology at the Perelman School of Medicine at the University of Pennsylvania, and Amy Justice, MD, PhD, Professor of General Medicine and Public Health at Yale School of Public Health, have been ...
Ushering in a New Era in Personalized Medicine
When Waun Ki Hong, MD, and his pregnant wife, Mihwa, made the journey from Korea to Manhattan in 1970, he had just $451 in his wallet, and the only job he could get was as an intern in Bronx-Lebanon Hospital Center, a community hospital in the Bronx. The work was grueling—24-hour shifts every 2...
Fitness: Can Exercise Lengthen Survival in Patients With Cancer?
Integrative Oncology is guest edited by Barrie R. Cassileth, MS, PhD, of Memorial Sloan Kettering Cancer Center, New York.
Regular physical activity has long been associated with decreased risk of disease, including many types of cancer. Such benefits may translate into increased life expectancy...
White Knuckling
The ASCO Post is pleased to reproduce installments of the “Art of Oncology” as published previously in the Journal of Clinical Oncology (JCO). These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays,...
Cabozantinib in Advanced Renal Cell Carcinoma
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs.
On April 25, 2016, a tablet formulation of cabozantinib...
The 10-Year Club
...
New FDA Rule Prohibits Sale of E-Cigarettes to Anyone Under Age 18 and Requires Warning Labels
A new rule extending U.S. Food and Drug Administration (FDA) oversight to all tobacco products, including electronic cigarettes (e-cigarettes), and banning the sale of these products to anyone under the age of 181 was hailed as a major advanced by many leaders of medical and health organizations....
Significant Increased Risk of Noncancer Hospitalization Following Diagnosis of Prostate Cancer in the Elderly
Elderly men had a significant increase in the risk of noncancer hospitalizations following the diagnosis of prostate cancer, according to a population-based retrospective cohort study conducted by Amit D. Raval, PhD, and colleagues at West Virginia University, Morgantown. Results were published in...
Relatives of Patients With Carcinoma of Unknown Primary at Increased Risk for This and Other Cancers
Relatives of patients with carcinoma of unknown primary are at increased risk of developing this type of cancer themselves and several other malignant neoplasms, including lung, pancreatic, and colon cancers; non-Hodgkin lymphoma; and myeloma, according to a study published in JAMA Oncology. “Some...
William J. Gradishar, MD, FACP, Named Deputy Director for Lurie Cancer Center Clinical Network
William J. Gradishar, MD, FACP, has been appointed Deputy Director for the Clinical Network of the Robert H. Lurie Comprehensive Cancer Center Network of Northwestern University. In this new role, Dr. Gradishar will oversee the coordination of clinical cancer services within Lurie Cancer Center’s...
ASCO Recognizes 2016 Recipients of FASCO Distinction
The Fellow of the American Society of Clinical Oncology (FASCO) distinction recognizes ASCO members for their extraordinary volunteer service, dedication, and commitment to ASCO. Their efforts benefit ASCO, the specialty of oncology, and, most importantly, patients with cancer.
The 2016...
